Literature DB >> 9245961

Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging.

H Ahlström1, H B Gehl.   

Abstract

PURPOSE: To describe and discuss previous and ongoing clinical and experimental studies with MnDPDP (Teslascan) as a pancreas-specific contrast agent for MR imaging.
MATERIAL AND METHODS: All results, both experimental and clinical, applying MnDPDP as a pancreas-specific contrast agent for MR imaging, were collected.
RESULTS: An increase of up to 100% in signal intensity was seen in normal pancreatic parenchyma, reaching its maximum approximately 25 min after the beginning of MnDPDP administration. Maximal enhancement was sustained for 4 h. Enhancement was only seen in the T1-weighted images. No enhancement was observed in tumours and an increase in contrast-to-noise of about 200% was obtained. The uptake of MnDPDP in pancreatitis compared with normal pancreatic parenchyma was decreased in an animal model.
CONCLUSION: Improved depiction and demarcation of pancreatic tumours with MR imaging were obtained after administration of MnDPDP. MR imaging with and without MnDPDP might be valuable for staging of pancreatitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9245961     DOI: 10.1080/02841859709172398

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.701


  4 in total

1.  Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions.

Authors:  Gul Eser; Aydin Karabacakoglu; Serdar Karakose; Cengiz Eser; Ertugrul Kayacetin
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

2.  Mangafodipir trisodium-enhanced MR imaging of pancreatic disease.

Authors:  Piero Boraschi; Francescamaria Donati; Roberto Gigoni; Davide Caramella; Ugo Boggi; Fabio Falaschi; Carlo Bartolozzi
Journal:  Eur Radiol       Date:  2006-01-19       Impact factor: 5.315

3.  Effect of new manganese contrast agent on tissue intensities in human volunteers: comparison of 0.23, 0.6 and 1.5 T MRI, a part of a phase I trial.

Authors:  E Chabanova; H S Thomsen; V Løgager; J M Moller; K Brage; K Fogh; J Bovin; J Elmig
Journal:  MAGMA       Date:  2004-07-16       Impact factor: 2.310

Review 4.  [Contrast agents in MRT. Substance, effects, pharmacology and validity].

Authors:  P Reimer; R Vosshenrich
Journal:  Radiologe       Date:  2004-03       Impact factor: 0.635

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.